Breaks Categories: News

MondayOct 07, 2024 2:34 pm

BioMedNewsBreaks — Roth Capital Partners with IBN as Official Media Sponsor of Annual Roth Healthcare Opportunities Conference

Roth Capital Partners (Roth MKM), a relationship-driven investment bank dedicated to serving growth companies and their investors, is partnering with IBN as an official media sponsor for this week’s third annual Roth Healthcare Opportunities Conference. The invitation-only, one-day conference is scheduled for Oct. 9, 2024, in New York City. According to the announcement, IBN will leverage its extensive corporate communications network to increase awareness of the conference, which is an exclusive platform that gathers together veteran investors with C-suite executives from public and private companies in the healthcare sector. “ROTH's upcoming conference is set to showcase some of the most…

Continue Reading

MondayOct 07, 2024 10:55 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Announces ‘Significant’ Extension and Expansion of Exclusive Distribution Agreement with OPKO Health

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, today announced that its original exclusive e-commerce distribution contract with OPKO Health Inc. (NASDAQ: OPK) has been extended for four years and expanded to include additional e-commerce platforms and digital and social media marketing across China. The original agreement allowed NextPlat to sell OPKO Health Europe’s nutraceutical and veterinary products on the Tmall Global e-commerce platform only. According to the announcement, the expanded contract also grants NextPlat the exclusive rights to sell and market OPKO products in Japan. “The significant extension and expansion of our agreement with OPKO is evidence of the…

Continue Reading

ThursdayOct 03, 2024 2:30 pm

BioMedNewsBreaks — 180 Life Sciences Corp. (NASDAQ: ATNF) Provides Update on Strategic Corporate Initiatives

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has released an update on several key initiatives, including announcing the acquisition of an advanced Gaming Technology Platform, positive progress on its Legacy CBD formulation and a strengthened balance sheet. According to the update, the company is shifting its focus as it enters the global iGaming market through its acquisition of a comprehensive intellectual property package, consisting of a complete back-end technology solution for online casino operations. In addition, the company anticipates retaining its current portfolio of biotechnology intellectual property as it reports positive study results exhibiting faster absorption and improved…

Continue Reading

ThursdayOct 03, 2024 2:18 pm

BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP), Carnegie Mellon University Partner to Potentially Revolutionize Donor Selection, Matching Processes with AI

TC BioPharm (NASDAQ: TCBP), a clinical stage biotechnology company developing allogeneic gamma-delta T cell therapies for cancer and other indications, today announced its sponsored research agreement with Carnegie Mellon University. Under the agreement, TC BioPharm is partnering with Dr. Wei Wu, a faculty member in the Ray and Stephanie Lane Computational Biology Department within the university’s School of Computer Science, and her lab to explore the potential use of artificial intelligence (“AI”) to enhance the donor selection and matching processes. “Dr. Wu and her laboratory are helping us tackle another ‘big problem’ with this endeavor, which has the potential to revolutionize…

Continue Reading

WednesdayOct 02, 2024 11:50 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Schedules Live Investor Webinar, Q&A Session

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, will be part of an upcoming live webinar hosted by RedChip Companies. Scheduled for October 17, 2024, at 4:15 p.m. ET, the exclusive event will feature Gareth Sheridan, Founder and CEO, and Serguei Melnik, Founder and President. Sheridan and Melnik will share insight into Nutriband’s current operations and upcoming milestones as well as field questions from listeners and investors. To register for the free webinar, visit https://ibn.fm/FAbNx To view the full press release, visit https://ibn.fm/WYRB1 About Nutriband Inc. Nutriband is primarily engaged in the development of a…

Continue Reading

WednesdayOct 02, 2024 9:30 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, and its wholly owned subsidiary, Clene Nanomedicine Inc., has closed on a registered direct offering and concurrent private placements. According to the announcement, the transactions consist of common stock and warrants and were with a healthcare-focused institutional investor and existing shareholders, including insiders. Gross proceeds of the offerings and placements totaled an estimated $7.3 million with the potential for additional capital through the future exercise of warrants. Clene also announced the amendment of its existing debt facility with Avenue Venture…

Continue Reading

TuesdayOct 01, 2024 2:58 pm

BioMedNewsBreaks — enVVeno Medical Corporation (NASDAQ: NVNO) Announces Pricing of $15M Underwritten Public Offering

enVVeno Medical (NASDAQ: NVNO), a late-clinical stage medical device company setting new standards of care for the treatment of venous diseases, recently announced the pricing of an underwritten public offering. Led by existing institutional investors, the offering involved the issuance and sale of 4,285,715 shares of the company’s common stock (or pre-funded warrants in lieu thereof) at a public offering price of $3.50 per unit. enVVeno expected to receive aggregate gross proceeds from the offering of about $15.0 million. The offering was anticipated to close on or about September 30, 2024, subject to customary closing conditions. To view the full…

Continue Reading

MondaySep 30, 2024 1:23 pm

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Filing of Three Patents Covering Combination Therapies for AD, PD

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has filed three new patents. According to the announcement, the patents cover combination therapies involving its lead compound, buntanetap, combined with Trulicity(R)(dulaglutide) and Viagra(R)(sildenafil), as well as a combination of all three. The company noted buntanetap inhibits the production of neurotoxic proteins and has been shown to improve cognition in early AD patients and halt cognitive decline in PD patients. “Our early data suggests a strong synergistic effect from combining these drugs, resulting in significant cognitive enhancement,” said Annovis…

Continue Reading

MondaySep 30, 2024 11:40 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements Totaling $7.3M

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, has entered into a securities purchase agreement. The company entered the agreement, which calls for the issue and sale of 742,626 shares of common stock (or prefunded warrants in lieu thereof) with a healthcare-focused institutional investor. The company also noted it had entered into additional agreement and placements with current investors as well as directors and officers of Clene. Gross proceeds from the transactions will total an estimated $7.3 million, before standard deductions and fees. Canaccord Genuity is acting…

Continue Reading

MondaySep 30, 2024 10:52 am

BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) CEO Joins Expert Panel at Long COVID, RECOVER TLC Workshop

Tonix Pharmaceuticals (NASDAQ: TNXP) CEO Seth Lederman, MD, participated at a recent event hosted by the Foundation for the National Institutes of Health (“FNIH”) and the National Institute of Allergy and Infectious Diseases (“NIAID”). According to an announcement from the fully integrated biopharmaceutical company, Lederman was a panel member at the “RECOVER Treating Long COVID – Navigating the Pathway Forward” workshop, which was held last week in Bethesda, Maryland. During the panel, experts discussed clinical trial endpoints that could provide meaningful data to support regulatory approval of potential Long COVID therapeutics. “We were honored to be invited to participate in the Long…

Continue Reading